New England Journal of Medicine· 2018Q1
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- 4,393citations
- Q1SCImago
- 2018year
Short summary
Adding atezolizumab to nab-paclitaxel significantly improved progression-free survival by 1.7 months (7.2 vs. 5.5 months) in patients with advanced triple-negative breast cancer, with a greater benefit seen in PD-L1 positive tumors.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Oncology
OncologyMedicine